SLBT
SL Science Holding Limited Ordinary Shares
NASDAQ · Healthcare · Biotechnology · US
$2.88
−8.57%Income statement
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 2.2M | 3.4M | 879.0K |
| Cost of Revenue | 1.4M | 1.4M | 141.0K |
| Gross Profit | 775.1K | 1.9M | 738.0K |
| Operating Expenses | |||
| R&D Expense | 2.1M | 2.0M | — |
| SG&A Expense | 2.5M | 1.1M | 641.2K |
| General & Admin Expense | 2.5M | 1.1M | 606.9K |
| Selling & Marketing Expense | — | 1.2K | 34.3K |
| Other Expenses | — | — | — |
| Total Operating Expenses | 4.6M | 3.1M | 641.2K |
| Cost and Expenses | 6.0M | 4.6M | 782.1K |
| Operating Income (EBIT) | (3.8M) | (1.2M) | 96.8K |
| Non-Operating | |||
| Interest Income | 40.3K | 45.3K | 1.6K |
| Interest Expense | — | — | — |
| Net Interest Income | 40.3K | 45.3K | 1.6K |
| Other Non-Op Income/Expense | 17.7K | 62.4K | 436.0K |
| Non-Operating Income (excl Interest) | — | — | — |
| EBT (Pre-Tax Income) | (3.8M) | (1.1M) | 532.9K |
| Income Tax Expense | (4.00) | 57.6K | 133.8K |
| Bottom Line | |||
| Net Income | (3.8M) | (1.2M) | 399.0K |
| Earnings from Cont. Ops | (3.8M) | (1.2M) | 399.0K |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (3.8M) | (1.2M) | 399.0K |
| Per Share | |||
| Basic EPS | $0.00 | $0.00 | $0.00 |
| Diluted EPS | $0.00 | $0.00 | $0.00 |
| Revenue Per Share | — | — | — |
| Shares | |||
| Basic Shares Outstanding | — | — | — |
| Diluted Shares Outstanding | — | — | — |
| Profitability Metrics | |||
| EBITDA | (3.7M) | (1.1M) | 134.0K |
| D&A | 93.7K | 47.2K | 37.2K |
| EBIT | (3.8M) | (1.2M) | 96.8K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025